TW202330029A - 配方 - Google Patents

配方 Download PDF

Info

Publication number
TW202330029A
TW202330029A TW111139754A TW111139754A TW202330029A TW 202330029 A TW202330029 A TW 202330029A TW 111139754 A TW111139754 A TW 111139754A TW 111139754 A TW111139754 A TW 111139754A TW 202330029 A TW202330029 A TW 202330029A
Authority
TW
Taiwan
Prior art keywords
antibody
arginine
stable liquid
hcl
polysorbate
Prior art date
Application number
TW111139754A
Other languages
English (en)
Chinese (zh)
Inventor
莎拉 馬奎特
克勞德 皮爾布姆
邁克爾約瑟夫愛德華 布南
Original Assignee
比利時商Ucb生物製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 比利時商Ucb生物製藥公司 filed Critical 比利時商Ucb生物製藥公司
Publication of TW202330029A publication Critical patent/TW202330029A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
TW111139754A 2021-10-21 2022-10-20 配方 TW202330029A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2115127.9A GB202115127D0 (en) 2021-10-21 2021-10-21 Formulations
GB2115127.9 2021-10-21

Publications (1)

Publication Number Publication Date
TW202330029A true TW202330029A (zh) 2023-08-01

Family

ID=78806159

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111139754A TW202330029A (zh) 2021-10-21 2022-10-20 配方

Country Status (17)

Country Link
US (1) US20250281403A1 (https=)
EP (1) EP4419077A1 (https=)
JP (1) JP2024539502A (https=)
KR (1) KR20240099316A (https=)
CN (1) CN118175989A (https=)
AR (1) AR127420A1 (https=)
AU (1) AU2022369042A1 (https=)
CA (1) CA3235492A1 (https=)
CL (1) CL2024001232A1 (https=)
CO (1) CO2024006206A2 (https=)
GB (1) GB202115127D0 (https=)
GE (2) GEAP202416521A (https=)
IL (1) IL312211A (https=)
MX (1) MX2024004873A (https=)
PE (1) PE20241192A1 (https=)
TW (1) TW202330029A (https=)
WO (1) WO2023067051A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006100679A2 (en) 2005-03-22 2006-09-28 Quark Pharmaceuticals, Inc. Recombinant antibodies against human type ii transglutaminase and uses thereof
GB2490655A (en) 2011-04-28 2012-11-14 Univ Aston Modulators of tissue transglutaminase
GB201209096D0 (en) 2012-05-24 2012-07-04 Medical Res Council Technology Compounds
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
CN109563161A (zh) * 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂

Also Published As

Publication number Publication date
CA3235492A1 (en) 2023-04-27
US20250281403A1 (en) 2025-09-11
IL312211A (en) 2024-06-01
PE20241192A1 (es) 2024-06-03
GEAP202416521A (en) 2024-07-25
CO2024006206A2 (es) 2024-05-30
AR127420A1 (es) 2024-01-24
CL2024001232A1 (es) 2024-09-13
WO2023067051A1 (en) 2023-04-27
KR20240099316A (ko) 2024-06-28
GB202115127D0 (en) 2021-12-08
MX2024004873A (es) 2024-05-06
JP2024539502A (ja) 2024-10-28
GEP20257801B (en) 2025-09-25
EP4419077A1 (en) 2024-08-28
CN118175989A (zh) 2024-06-11
AU2022369042A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
AU2015260758B2 (en) Antibody formulation
JP2022540781A (ja) 抗cd47/pd‐l1二重特異性抗体を含む製剤、その調製方法及び使用
JP2020180156A (ja) VE−PTP(HPTP−β)を標的化するヒト化モノクローナル抗体
JP2018507202A (ja) モノクローナル抗体のための安定的な液体製剤
CN107080843A (zh) 眼病的治疗
CN105555311A (zh) 稳定的抗体组合物
CN111704672A (zh) 抗血浆激肽释放酶抗体
WO2023061424A1 (en) Pharmaceutical formulation comprising anti-ox40 monoclonal antibody
TW202330029A (zh) 配方
EP4536280A2 (en) Anti-igf-1r antibody compositions
HK40109619A (zh) 制剂
TW202323288A (zh) 配方
HK40109650A (zh) 制剂
US20260008849A1 (en) Antibody formulations
BR122025018375A2 (pt) Fragmentos de cadeia única de anticorpo anti-c3
HK40118051A (zh) Csf-1r抗体制剂
HK40107164A (zh) Csf-1r抗体制剂
HK1108132A1 (en) Anti a beta antibody formulation
HK1108132B (en) Anti a beta antibody formulation